The Significance of Achieving Optimal Treatment Targets in Atopic Dermatitis - Episode 3
Impact of JAK Inhibitors on Itch and Quality of Life in Atopic Dermatitis
Published on:
Shawn Kwatra, MD, provides an overview of oral JAK inhibitors for the treatment of atopic dermatitis, highlighting data from clinical trials.
Video content above is prompted by the following questions:
- What characteristics, if any, of oral JAK inhibitors make them an attractive option for improving QoL in patients with AD?
- Discuss clinical trial data with oral JAK inhibitors, upadacitinib and abrocitinib, and improvements in patient-reported outcomes in atopic dermatitis.
- Please review data from real-world studies that have evaluated effectiveness of oral JAK inhibitors (upadacitinib and abrocitinib) through physician and patient-reported outcomes.
